Abstract
Cancer immunotherapy uses the host′s immune system to mobilize immune cells to recognize and eventually eliminate cancer cells. At present, studies in terms of cancer immunotherapy mainly focus on programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) antibody, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, chimeric antigen receptor T-cell immunotherapy (CAR-T), T cell receptor Immunotherapy (TCR-T), etc. Despite the fact that cancer immunotherapies elicit unprecedented durable responses in clinical therapy, they appear to be ineffective to some patients. In addition, some responders relapse and show resistance to immunotherapies even if their symptoms are relieved for a time. Resistance to cancer immunotherapy can be categorized into primary, adaptive and acquired, which can occur in every stage during the process of anti-tumor response. In this review, we discuss the known mechanisms of resistance and provide a rationale for the use of combination therapy to overcome resistance. Key words: Immunotherapy; Immune checkpoint; Resistance mechanism
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
